Re: Priority review Voucher sales by srpt.
I think the voucher is generic. The pediatric reference is to its source and not its intended use. There is more than one way to earn a priority review voucher.
Pricing is supply vs demand. A lot more companies are chasing rare diseases than in the past due to the extremely high prices being paid by the government and insurance companies for treatments. So more expectations of vouchers being generated. Pricing also affected by how slow the FDA acts on conventional approvals. The worse the FDA delay, the more valuable the voucher. Remains to be seen whether Trump administration speeds drug approvals (would decrease value of vouchers, all else being equal)